Aberdeen Group plc Purchases 88,853 Shares of Charles River Laboratories International, Inc. $CRL

Aberdeen Group plc grew its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 1,090.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 97,001 shares of the medical research company’s stock after purchasing an additional 88,853 shares during the period. Aberdeen Group plc owned approximately 0.20% of Charles River Laboratories International worth $19,350,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Charles River Laboratories International by 0.5% in the third quarter. Vanguard Group Inc. now owns 5,839,743 shares of the medical research company’s stock valued at $913,686,000 after purchasing an additional 27,989 shares in the last quarter. Ariel Investments LLC increased its position in shares of Charles River Laboratories International by 28.6% in the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock valued at $214,751,000 after acquiring an additional 314,572 shares during the last quarter. Invesco Ltd. increased its position in shares of Charles River Laboratories International by 1.0% in the third quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company’s stock valued at $195,446,000 after acquiring an additional 12,035 shares during the last quarter. Bank of America Corp DE increased its position in shares of Charles River Laboratories International by 13.4% in the third quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock valued at $182,017,000 after acquiring an additional 137,335 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Charles River Laboratories International by 11.9% in the third quarter. Dimensional Fund Advisors LP now owns 1,130,905 shares of the medical research company’s stock valued at $176,909,000 after acquiring an additional 120,207 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Trading Down 3.1%

Shares of CRL stock opened at $168.45 on Tuesday. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. The stock has a market cap of $8.31 billion, a P/E ratio of -56.91, a price-to-earnings-growth ratio of 2.11 and a beta of 1.61. The stock has a 50 day simple moving average of $173.46 and a 200 day simple moving average of $181.56. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.06. The business had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CRL. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Evercore boosted their price target on Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. TD Cowen lowered their price target on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Wall Street Zen downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Finally, Mizuho lowered their price target on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research report on Friday, February 20th. Ten equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $206.15.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.